On March 28, a new article published in JCO Clinical Cancer Informatics (JCO CCI), “Survival Disparities by Hospital Volume among American Women with Gynecologic Cancers” by Brandon-Luke Seagle, MD, et al., that finds that women with ovarian, endometrial or cervical cancer have significantly increased rates of survival if they are treated at higher-volume hospitals.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO's peer-reviewed journals now follow a continuous publication schedule, publishing the newest content from each journal online daily.
On March 27, 2017, the U.S. Food and Drug Administration approved niraparib (ZEJULA™, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
The Centers for Medicare & Medicaid Services (CMS) posted new resources to the Quality Payment Program (QPP) website to help clinicians successfully participate in the first year of the QPP.
On March 15, HIMMS News published an article authored by CancerLinQ LLC Chief Operating Officer Rich Ross that discusses the need for interoperability to for big data efforts to be successful.
On March 23, 2017, the U.S. Food and Drug Administration granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. This is the first FDA-approved product to treat this type of cancer.
The U.S. cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to ASCO's fourth annual State of Cancer Care in America report released March 22, 2017.
On March 21, Lancet Public Health published a study on the 2003 global tobacco control treaty’s impact on the adoption of tobacco reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed to it to implement strong evidence-based policies. While the US did sign on in 2004, it has never ratified this treaty.
STAT – a national publication focused on health and medicine – published an op-ed by ASCO President Daniel F. Hayes, MD, FACP, FASCO, on the critical importance of providing robust funding for the National Institutes of Health (NIH). The op-ed responds to the Administration's "budget blueprint," which proposes at 20 percent cut to the NIH.
In a congressional briefing on Capitol Hill, ASCO presented the State of Cancer Care in America: 2017, which examines significant changes occurring in the cancer care delivery system.
QOPI Certification Program LLC (QCP), an affiliate of ASCO that runs the QOPI Certification Program™, and the Foundation for Excellence and Quality in Oncology (ECO), a nonprofit foundation in Spain, have launched an effort to expand the QOPI Certification Program to Spain. Through the collaboration between ECO and QCP, Spanish oncology practices will be able to apply for QOPI Certification.
On March 22, ASCO’s big data initiative, CancerLinQ®, and newest journal, JCO Clinical Cancer Informatics (JCO CCI), will be highlighted at the Cancer Informatics for Cancer Centers (CI4CC) 2017 Spring Symposium and Workshop. This year’s meeting takes a focus on the role of registries in the national cancer data ecosystem.
On March 15, the Campaign for Tobacco-Free Kids, American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, and American Lung Association issued a new report titled “The Flavor Trap: How Tobacco Companies Are Luring Kids with Candy-Flavored E-Cigarettes and Cigars.”
We soundly oppose President Trump’s budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH’s funding by nearly 20 percent will devastate our nation’s already fragile federal research infrastructure and undercut a longstanding commitment to biomedical science that has fueled advances in cancer prevention, diagnosis, and treatment.